ROGERIO DE SOUZA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Cardio-Pneumologia, Faculdade de Medicina - Docente
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina - Líder
Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/09 - Laboratório de Pneumologia, Hospital das Clínicas, Faculdade de Medicina - Líder
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality(2018) MCLAUGHLIN, Vallerie V.; HOEPER, Marius M.; CHANNICK, Richard N.; CHIN, Kelly M.; DELCROIX, Marion; GAINE, Sean; GHOFRANI, Hossein-Ardeschir; JANSA, Pavel; LANG, Irene M.; MEHTA, Sanjay; PULIDO, Tomas; SASTRY, B. K. S.; SIMONNEAU, Gerald; SITBON, Olivier; SOUZA, Rogerio; TORBICKI, Adam; TAPSON, Victor F.; PERCHENET, Loic; PREISS, Ralph; VERWEIJ, Pierre; RUBIN, Lewis J.; GALIE, NazzarenoBACKGROUND Registry data suggest that disease progression in pulmonary arterial hypertension (PAH) is indicative of poor prognosis. However, the prognostic relevance of PAH-related morbidity has not been formally evaluated in randomized controlled trials. OBJECTIVES The purpose of these analyses was to assess the impact of morbidity events on the risk of subsequent mortality using the landmark method and data from the SERAPHIN and GRIPHON studies. METHODS For each study, the risk of all-cause death up to the end of the study was assessed from the landmark time point (months 3, 6, and 12) according to whether a patient had experienced a primary endpoint morbidity event before the landmark. Each analysis was conducted using data from all patients who were available for survival follow-up at the landmark. RESULTS In the SERAPHIN study, on the basis of the 3-month landmark time point, patients who experienced a morbidity event before month 3 had an increased risk of death compared with patients who did not (hazard ratio [HR]: 3.39; 95% confidence interval [CI]: 1.94 to 5.92). In the GRIPHON study, on the basis of the 3-month landmark time point, there was also an increased risk with a HR of 4.48; (95% CI: 2.98 to 6.73). Analyses based on 6-month and 12-month landmarks also showed increased risk in patients who experienced morbidity events, albeit with a reduced HR. CONCLUSIONS These results demonstrate the prognostic relevance of PAH-related morbidity as defined in the SERAPHIN and GRIPHON studies, highlighting the importance of preventing disease progression in patients with PAH and supporting the clinical relevance of SERAPHIN and GRIPHON morbidity events. (Study of Macitentan [ACT-064992] on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension [SERAPHIN]; NCT00660179; Selexipag [ACT-293987] in Pulmonary Arterial Hypertension [GRIPHON]; (c) 2018 The Authors.
- Updated Clinical Classification of Pulmonary Hypertension(2013) SIMONNEAU, Gerald; GATZOULIS, Michael A.; ADATIA, Ian; CELERMAJER, David; DENTON, Chris; GHOFRANI, Ardeschir; SANCHEZ, Miguel Angel Gomez; KUMAR, R. Krishna; LANDZBERG, Michael; MACHADO, Roberto F.; OLSCHEWSKI, Horst; ROBBINS, Ivan M.; SOUZA, RogieroIn 1998, a clinical classification of pulmonary hypertension (PH) was established, categorizing PH into groups which share similar pathological and hemodynamic characteristics and therapeutic approaches. During the 5th World Symposium held in Nice, France, in 2013, the consensus was reached to maintain the general scheme of previous clinical classifications. However, modifications and updates especially for Group 1 patients (pulmonary arterial hypertension [PAH]) were proposed. The main change was to withdraw persistent pulmonary hypertension of the newborn (PPHN) from Group 1 because this entity carries more differences than similarities with other PAH subgroups. In the current classification, PPHN is now designated number 1. Pulmonary hypertension associated with chronic hemolytic anemia has been moved from Group 1 PAH to Group 5, unclear/multifactorial mechanism. In addition, it was decided to add specific items related to pediatric pulmonary hypertension in order to create a comprehensive, common classification for both adults and children. Therefore, congenital or acquired left-heart inflow/outflow obstructive lesions and congenital cardiomyopathies have been added to Group 2, and segmental pulmonary hypertension has been added to Group 5. Last, there were no changes for Groups 2, 3, and 4. (C) 2013 by the American College of Cardiology Foundation
- Updated clinical classification of pulmonary hypertension (vol 62, pg D34, 2013)(2014) SIMONNEAU, G.; GATZOULIS, M. A.; ADATIA, I; CELERMAJER, D.; DENTON, C.; GHOFRANI, A.; SANCHEZ, Gomez M. A.; KUMAR, R. K.; LANDZBERG, M.; MACHADO, R. F.; OLSCHEWSKI, H.; ROBBINS, I. M.; SOUZA, R.
- Pulmonary Hypertension of Sickle Cell Disease Beyond Classification Constraints Reply(2014) SOUZA, Rogerio; SIMONNEAU, Gerald
- Management of Pulmonary Arterial Hypertension(2015) MCLAUGHLIN, Vallerie V.; SHAH, Sanjiv J.; SOUZA, Rogerio; HUMBERT, MarcPulmonary hypertension (PH) is common and may result from a number of disorders, including left heart disease, lung disease, and chronic thromboembolic disease. Pulmonary arterial hypertension (PAH) is an uncommon disease characterized by progressive remodeling of the distal pulmonary arteries, resulting in elevated pulmonary vascular resistance and, eventually, in right ventricular failure. Over the past decades, knowledge of the basic pathobiology of PAH and its natural history, prognostic indicators, and therapeutic options has exploded. A thorough evaluation of a patient is critical to correctly characterize the PH. Cardiac studies, including echocardiography and right heart catheterization, are key elements in the assessment. Given the multitude of treatment options currently available for PAH, assessment of risk and response to therapy is critical in long-term management. This review also underscores unique situations, including perioperative management, intensive care unit management, and pregnancy, and highlights the importance of collaborative care of the PAH patient through a multidisciplinary approach. (C) 2015 by the American College of Cardiology Foundation.
conferenceObject SAFETY AND EFFICACY OF MACITENTAN IN ELDERLY PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH): INSIGHTS FROM SERAPHIN(2020) LANGLEBEN, David; CHANNICK, Richard; DELCROIX, Marion; GALIE, Nazzareno; GHOFRANI, Ardeschir; JANSA, Pavel; MEHTA, Sanjay; PULIDO, Tomas; SOUZA, Rogerio; SIMONNEAU, Gerald; SASTRY, B. K. S.; TORBICKI, Adam; MARTIN, Nicolas; PERCHENET, Loic; SITBON, Olivier